Sign in

CIK 0002023658 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Bicara Therapeutics Inc.

Sign in to watch
Ticker
BCAX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
617-468-4219
Business address
116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Planned sale President and COO sold 3,828 shares at $18.10 ($69,296)
  7. 4 Planned sale Chief Financial Officer sold 1,882 shares at $18.15 ($34,162)
  8. 4 Planned sale President and COO sold 149 shares at $18.02 ($2,685)
  9. 4 Option exercise President and COO acquired 25,000 shares (option exercise)
  10. 4 Option exercise Chief Medical Officer acquired 19,789 shares (option exercise)
  11. 4 Planned sale Chief Financial Officer sold 9,200 shares at $18.31 ($168,492)
  12. 4 Option exercise Chief Executive Officer acquired 29,500 shares (option exercise)
  13. 4 Planned sale President and COO sold 12,500 shares at $18.68 ($233,548)
  14. 4 Planned sale Chief Financial Officer sold 18,400 shares at an average $18.54 ($341,074)
  15. 4 Planned sale President and COO sold 12,500 shares at $18.05 ($225,588)
  16. 4 Planned sale Chief Executive Officer sold 41,163 shares at $18.86 ($776,429)
  17. 4 Planned sale Chief Medical Officer sold 11,000 shares at an average $18.65 ($205,108)
  18. 4 Planned sale Chief Executive Officer sold 24,103 shares at $18.83 ($453,761)
  19. 4 Planned sale President and COO sold 12,500 shares at $18.16 ($226,943)
  20. 4 Planned sale Chief Executive Officer sold 24,734 shares at an average $18.88 ($466,936)

Page 3 of 6 · 107 filings